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Urine metabolomic analysis to detect 
metabolites associated with the 
development of contrast induced 
nephropathy
Deborah B. Diercks1, Kelly P. Owen2, Jeffrey A. Kline3, Mark E. Sutter2
Department of Emergency Medicine, 1UT Southwestern Medical Center, Dallas, TX; 2Davis Medical Center, 
University of California, Sacramento, CA; 3Indiana University, Indianapolis, IN, USA
Objective Contrast induced nephropathy (CIN) is a result of injury to the proximal tubules. The 
incidence of CIN is around 11% for imaging done in the acute care setting. We aim to analyze 
the metabolic patterns in the urine, before and after dosing with intravenous contrast for com-
puted tomography (CT) imaging of the chest, to determine if metabolomic changes exist in pa-
tients who develop CIN.
Methods A convenience sample of high risk patients undergoing a chest CT with intravenous 
contrast were eligible for enrollment. Urine samples were collected prior to imaging and 4 to 6 
hours post imaging. Samples underwent gas chromatography/mass spectrometry profiling. Peak 
metabolite values were measured and data was log transformed. Significance analysis of micro-
arrays and partial least squares was used to determine the most significant metabolites prior to 
CT imaging and within subject. Analysis of variance was used to rank metabolites associated 
with temporal change and CIN. CIN was defined as an increase in serum creatinine level of ≥ 0.5 
mg/dL or ≥ 25% above baseline within 48 hours after contrast administration.
Results We sampled paired urine samples from 63 subjects. The incidence of CIN was 6/63 (9.5%). 
Patients without CIN had elevated urinary citric acid and taurine concentrations in the pre-CT 
urine. Xylulose increased in the post CT sample in patients who developed CIN.
Conclusion Differences in metabolomics patterns in patients who do and do not develop CIN 
exist. Metabolites may be potential early identifiers of CIN and identify patients at high-risk for 
developing this condition prior to imaging.
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What is already known
Contrast induced nephropathy occurs in acute care and current diagnostic 
tools result in a delay in diagnosis. 
What is new in the current study
Using urine metabolomics patterns, we were able to identify patients at risk for 
contrast induced nephropathy.
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INTRODUCTION
The use of computed tomography (CT) has increased over 200% 
in the last decade.1 Contrast induced nephropathy (CIN) that de-
velops as a result of imaging using intravenous contrast enhance-
ment, or other diagnostic procedures, has been reported to be the 
third leading cause of acute renal failure in hospitalized patients. 
It has been hypothesized that this occurs as a result of direct tox-
icity, oxidative stress, and ischemic injury.2 Numerous studies have 
evaluated the incidence of CIN in patients undergoing angiogra-
phy. There are limited studies in the acute care setting; however, 
Mitchell et al.1 reported the incidence of CIN in patients undergo-
ing chest CT with contrast for the evaluation of pulmonary em-
boli to be close to 10%. Studies have identified patient charac-
teristics associated with the risk of developing CIN, but there are 
limited diagnostic tools that can identify a patient at risk in the 
pre-CT or early post-CT time frame.1 Therefore, a tool that could 
identify early risk factors for CIN would be valuable for patient 
care.
 Metabolomic profiling is the identification of small molecule 
metabolites that are altered in response to injury. We have previ-
ously shown that urine metabolomic profiles differ in patients be-
fore and after intravenous contrast administration for CT scan.3 
We hypothesize that metabolomic profiles will differ between 
those patients who develop CIN and those who do not after con-
trast administration. In addition we believe that metabolomics 
profiles prior to imaging may identify subjects who will go on to 
develop CIN and are therefore at higher risk. The specific aim of 
this pilot study is to determine if metabolomics profiles differ in 
patients who develop CIN after intravenous contrast administra-
tion for CT scan versus those who do not. Additionally, our goal 
was to identify specific urinary metabolites that warrant further 
investigation.
METHODS
This is a pilot study of prospectively identified patients undergo-
ing a CT of the chest with intravenous contrast during their 
emergency department (ED) evaluation. The study was approved 
by the University of California, Davis institutional review boards.
Study setting and selection of participants
A convenience sample of patients was enrolled. To be eligible for 
the study, patients had to be >18 years old, undergoing CT angi-
ography of the chest and have at least 1 of the following high 
risk features for CIN: diabetes,4,5 coronary artery disease,1 conges-
tive heart failure,4,6 chronic kidney disease (baseline creatinine 
>1.5 mg/dL or glomerular filtration rate <60 mL/min/1.73 m2). 
Past medical history was confirmed by chart review if available, 
or patient report. In addition, patients must have been given a 
physician assessment of >75% likelihood of hospital admission. 
 Patients were excluded from the study if they had an estimat-
ed glomerular filtration rate <15 mL/min/1.73 m2, a history of 
organ transplantation, were currently on immunosuppressive 
medications, were septic or on antibiotic therapy, had a history of 
or were currently receiving dialysis of any type, had an exposure 
to iodinated contrast within 3 days prior to the study, had more 
than one contrast CT ordered, or had multiple doses of contrast 
given.
 Patients were managed according to the treating provider rec-
ommendations. No intervention was requested as part of this 
study. There was no institutional standard for mandatory fluid 
administration or use of N-acetylcysteine prior to CT scanning. 
Iodinated contrast
All patients received approximately 120 mL of intravenous iodin-
ated contrast material (iohexol; Omnipaque 350, GE Healthcare, 
Chicago, IL, USA) that was administered via computer-controlled 
automated power injector at 4 mL per second. 
Data collection and processing
ED data were collected prospectively after patients were identified 
as fulfilling inclusion and exclusion criteria, and informed consent 
was obtained. Data collection included race, demographics, dietary 
history, medical history, physical examination, and electrocardio-
gram findings, as documented by the treating emergency physi-
cian. Medical history was confirmed through patient self-report 
and review of the medical record when available. Medications ad-
ministered in the ED and before arrival were also recorded. Final 
ED diagnosis was based on the treating physician’s impression. No 
additional laboratory tests were mandated as a part of the trial 
study and the treating physician ordered all tests, except urinary 
metabolomics analysis, according to their clinical judgment. Chest 
radiography findings documented by a board-certified radiologist, 
and laboratory tests, were obtained from the medical record. Urine 
samples were collected as a midstream sample or via a foley bag 
prior to CT scan and 4 to 6 hours post imaging. Samples were ali-
quoted into 2 mL samples and frozen at -80˚C. 
 All patients were followed by chart review throughout their 
index stay to document in-hospital events. Serum creatinine lev-
els were recorded at presentation, and at 24 and 48 hours.
 The outcome measure was the presence CIN, which was de-
fined as an increase in serum creatinine level of ≥0.5 mg/dL or 
≥25% above baseline within 48 hours after contrast administra-
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tion. For labeling purposes, patients who developed CIN are here-
after referred to as cases and patients without CIN are controls.
Gas chromatography mass spectometry analysis
Urine samples required no preparation prior to freezing. Neat 
urine samples were lyophilized without further pretreatment. 
Twenty microliter of 40 mg/mL methoxylamine hydrochloride in 
pyridine was added to the dried samples, and samples were agi-
tated at 30°C for 30 min. Subsequently, 180 μL of trimethylsi-
lylating agent N-methyl-N-trimethylsilyltrifluoroacetamide was 
added, and samples were agitated at 37°C for 30 minutes. Gas 
chromatography mass spectometry analysis was performed using 
a Agilent 6890 N gas chromatograph (Agilent Technologies, At-
lanta, GA, USA) interfaced to a time-of-flight Pegasus III mass 
spectrometer (Leco, St. Joseph, MI, USA).7-9 Automated injections 
were performed with a programmable robotic Gerstel MPS2 mul-
tipurpose sampler (Mülheim an der Ruhr, Germany). Initial peak 
detection and mass spectrum deconvolution was performed with 
ChromaTOF software ver. 2.25 (Leco), and later samples were ex-
ported to the netCDF format for further data evaluation with 
MZmine and XCMS. To be considered a known metabolite, mo-
lecular compounds must be identified with >50% certainty. If 
this degree of certainty was unobtainable, identified compounds 
were given the name “unknown”, followed by a numeric number. 
Statistical analysis
Continuous data was presented as medians and interquartile range. 
The statistical analysis was performed on (natural) log-transformed 
data that was range scaled (mean-centered and divided by the 
range of each variable) to adjust for concentration differences of 
metabolites in the sample. The primary objective was to identify 
metabolomics differences based on the presence of CIN post CT 
scan. Transformed data were plotted to assess for normality. 
Pre-CT analysis
A t-test was performed to determine differences in the metabo-
lites, with a P-value threshold of <0.05. Partial least squares-dis-
criminate analysis (PLS-DA) was used to identify metabolites as-
sociated with CIN (class difference). The features were ranked 
based on their regression coefficients and plotted by their variable 
of importance in projection score. The variable of importance in 
projection score is a weighted sum of squares and takes into the 
account the amount of explained Y-variation in each dimension. 
Significance analysis of microarrays (SAM) is designed to address 
the false discovery rate when running multiple tests on high-di-
mensional microarray data. SAM assigns a significance score to 
each variable based on its change relative. The optimal delta was 
selected based on the target identification of 10 significant me-
tabolites. The false discovery rate is the proportion of the metabo-
lite change attributed to chance alone.
 
Post imaging analysis
Univariate analysis methods are the most common methods used 
for exploratory data analysis. For two- factor data, the basic ap-
proach is two-way analysis of variance (ANOVA). In time series, 
data samples are measured from the same subjects from different 
time points and therefore within subject ANOVA was used. Analy-
sis was performed in Metaboanalyst 2.0 (Edmonton, Alberta, 
Canada).10
 Multivariate empirical Bayes time-series analysis (MEBA) was 
developed for analysis of microarray time-course data and allows 
grouping by a pre-specified condition. MEBA compares the pro-
files of the different time series of the metabolites. The outcome 
is a ranked list of all metabolites that show differences in their 
temporal profile between the experimental groups. Analysis was 
performed in Metaboanalyst 2.0.
RESULTS
A total of 100 subjects were consented. Thirty-seven were ex-
Table 1. Demographics and patient characteristics
Variable Value
Age (yr) 54 (50–66)
Male  31 (49.2)
Caucasian race 35 (55.6)
Smoker (current) 18 (28.6)
Heart failure 21 (33.3)
Diabetes 26 (41.3)
Hypertension 42 (66.7)
Coronary artery disease 16 (25.8)
Heart rate (bpm) 84 (73–109)
Systolic blood pressure (mmHg) 136 (119–157)
Serum creatinine (mg/dL) 0.94 (0.74–1.14)
Serum BUN (mg/dL) 13 (10–18)
Final diagnosis
Chest pain-not otherwise specified or ACS
Heart failure
Pneumonia
Asthma/COPD
Muskuloskeletal
Pulmonary emboli
Syncope
Arrhythmia
Other (unknown, mass, etc.)
22 (34.9)
11 (17.5)
8 (12.7)
4 (6.4)
4 (6.4)
3 (4.8)
2 (3.2)
2 (3.2)
6 (11.1)
Hours from CT to urine collection 4.63 (4–7)
Values are presented as median (interquartile range) or number (%).
BUN, blood urea nitrogen; ACS, acute coronary syndrome; COPD, chronic obstruc-
tive pulmonary disease; CT, computed tomography.
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cluded due to lack of pre and post urine samples or lack of 24-
hour creatinine value. The cohort comprised 63 patients, 31 were 
Table 2. Important metabolites identified by t-test pre-CT
P-value -log10 FDR
Uracil 0.00044094 3.3556 0.038075
Uric acid 0.00054007 3.2676 0.038075
N-acetyllysine 0.0026186 2.5819 0.12307
Tyrosine 0.0036236 2.4409 0.12773
Ribose 0.0057628 2.2394 0.12982
Glycine 0.0059732 2.2238 0.12982
Citric acid 0.0064451 2.1908 0.12982
4-Hydroxymandelic acid 0.0076673 2.1154 0.13514
Ethanolamine 0.010374 1.9841 0.16252
N-acetylaspartic acid 0.014264 1.8458 0.20112
Galactinol 0.025339 1.5962 0.25063
Lysine 0.026522 1.5764 0.25063
Beta-alanine 0.028332 1.5477 0.25063
Glycolic acid 0.028472 1.5456 0.25063
2,3-Dihydroxybutanoic acid NIST 0.028855 1.5398 0.25063
Alpha ketoglutaric acid 0.031523 1.5014 0.25063
Lauric acid 0.037764 1.4229 0.25063
Xylulose NIST 0.039411 1.4044 0.25063
Glycocyamine 0.043575 1.3608 0.25063
Pseudo uridine 0.043869 1.3578 0.25063
N-acetyl-glutamic acid 0.044078 1.3558 0.25063
Alanine 0.04412 1.3554 0.25063
Urea 0.044171 1.3549 0.25063
5-Hydroxymethyl-2-furoic acid NIST 0.045294 1.344 0.25063
CT, computed tomography; FDR, false discovery rate; NIST, National Institute of 
Standards and Technology.
Fig. 1. Partial least squares analysis pre- computed tomography urine with variable 
importance in projection (VIP) scores and association with the development of contrast 
induced nephropathy (case). 
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Fig. 2. Significance analysis of microarrays (SAM) shows 8 significant 
metabolites identified in the pre-computed tomography urine sample 
associated with contrast induced nephropathy. These are presented in 
Table 3. FDR, false discovery rate.
males (49.2) and the median age was 54 years (interquartile 
range 50 to 66). Of the 63 subjects, 6 met the criteria for CIN 
(cases), leaving 57 controls. The most common reported final ED 
diagnosis was chest pain not otherwise specified/acute coronary 
syndrome (Table 1).
Pre-CT urine analysis
In the pre-CT urine analysis, we identified nine metabolites asso-
ciated with the outcome measure with a P-value <0.01 (Table 2). 
Of these nine, uric acid and uracil were the most significant. PLS-
DA ranked the most significant metabolites associated with the 
cases or controls. This analysis showed that higher citric acid and 
taurine levels were associated with controls (Fig. 1).
 Uracil and uric acid were also identified metabolites associated 
with CIN in the SAM analysis (Table 3 and Fig. 2). Differences be-
tween cases and controls of the most significant peak metabo-
lites found in the SAM analysis and PLS-DA are presented in Fig. 3.
Table 3. Significance analysis of microarrays significant metabolites
D-value
Standard  
deviation
Unadjusted 
P-value
Q-value
Uracil 3.7487 0.36036 0.00078014 0.012017
Uric acid 3.684 0.38714 0.00085106 0.012017
N-acetyllysine 3.1585 0.28349 0.0032624 0.027467
Tyrosine 3.0446 0.31453 0.0042553 0.027467
Ribose 2.8777 0.40455 0.0057447 0.027467
Glycine 2.8645 0.52686 0.0060284 0.027467
Citric acid 2.8366 0.56668 0.0068085 0.027467
4-Hydroxymandelic acid 2.7721 0.38061 0.0082979 0.029291
SAM plot for delta=1.3
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Fig. 3. Box plots of metabolites presented as adjusted and log transformed comparing patients with contrast induced nephropathy (case) and without 
(control). (A) Citric acid, (B) uric acid, (C) uracil, and (D) taurine. 
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Fig. 4. Top 4 metabolites in the Multivariate Bayesian time-series analysis in post-imaging urine. (A) Threonic acid, (B) xylonic acid, (C) glycine, and (D) 
uracil.  CT, computed tomography.
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Post-CT analysis
The 4 top metabolites ranked showing temporal differences be-
tween cases and controls are xylonic acid, glycine, uracil and thre-
onic acid (Fig. 4). Using ANOVA within a subject, xylulose was the 
most important metabolite (Table 4).
DISCUSSION
Renal function has been noted to become altered in up to 4% to 
20% of all patients in hospitalized patients.11-13 Contrast-induced 
nephropathy is a leading cause of acute renal failure in this hos-
pitalized patient population.14 Because of the late rise in serum 
creatinine, there is a temporal delay in identification of injury. In 
this study we did find differences in metabolomics profiles in those 
who would go on to develop CIN compared to those who did not 
develop CIN. Additionally, specific metabolites were significantly 
different between patients developing CIN and those that did 
not. When pre-contrast urine was analyzed concentrations of 
citric acid and taurine were higher in those that did not develop 
CIN. When evaluating urine metabolite changes pre and post CT, 
xylulose, glycine, uric acid, and threonic acid were significant.
 This study suggests that changes in the urine metabolomics 
profile of patients with CIN occur, and identifies metabolites for 
further evaluation in the development of CIN after CT imaging of 
the chest with contrast. The mechanisms behind the development 
of CIN are complex. They include potential interplay of vasocon-
striction, oxidative stress, and direct tubular toxicity leading to 
hypoxia of the outer medulla.15-21 Studies have shown that the 
contrast administration not only results in vasoconstriction, but 
toxicity results in proximal tubularvacuolar transformation, inter-
stitial edema and tubular degeneration.22 In addition changes to 
the proximal tubules result in alterations in electrolyte homeo-
stasis. Given the complex pathophysiology behind the renal ef-
fects of intravenous contrast, multiple markers may identify inju-
ry, as different effects occur on urinary enzymes and tubular lo-
cation.23,24
 Given the numerous pathologic mechanisms behind the devel-
opment of CIN, it is not surprising that multiple statistically sig-
nificant metabolites were identified. Several of these identified 
metabolites either mitigate oxidative damage or are a marker of 
an oxidative stress. Our results showed that subjects with higher 
levels of urea developed more CIN whereas higher levels of citric 
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Table 4. Significant variables in the within subject ANOVA analysis
Phenotype Time Interaction
Xylulose NIST 0.3629 1.70E-05 0.96624
Succinic acid 0.6543 0.046879 0.59449
Galactinol 0.71555 0.044967 0.37627
Levoglucosan 0.72951 0.033927 0.37627
Pinitol NIST 0.87585 0.044698 0.50307
Pyrogallol 0.94838 0.00037119 0.37627
Glycerol-3-galactoside 0.94838 0.0079989 0.37627
Phenol 0.94838 0.0082768 0.68288
UDP-glucuronic acid 0.94838 0.026679 0.37627
Quinic acid 0.94838 0.026679 0.37627
Pimelic acid 0.94838 0.026679 0.41876
Sucrose 0.94838 0.044698 0.37627
1-Desoxypentitol NIST 0.94838 0.044698 0.93117
2,5-Furandicarboxylic acid NIST 0.98932 0.0082768 0.37627
7-Methylguanine NIST 0.98932 0.044698 0.99737
3,4-Dihydroxyphenylacetic Acid 0.9955 0.0018637 0.14347
Catechol 0.9955 0.036242 0.68288
Furoylglycine NIST 0.99802 0.01496 0.6106
ANOVA, analysis of variance; NIST, National Institute of Standards and Technolo-
gy; UDP, uridine diphosphate.
acid and taurine developed less. 
 As damage to the kidney occurs, proteins (containing nitrogen) 
are excreted.22 Both citric acid and taurine possess anti-oxidant 
properties and taurine has been shown to attenuate CIN in a ca-
nine model.25 Additionally, when evaluating metabolites with sig-
nificant changes between pre and post intravenous contrast, xy-
lulose and threonic acid were significant. Xylulose is a pentose 
sugar that oxidizes to form xylonic acid.26 Our results showed 
that Xylonic acid levels rose post intravenous contrast demon-
strating the process of oxidation. Similar to xylonic acid, threonic 
acid is the metabolic breakdown product of the anti-oxidant 
ascorbic acid (vitamin C), and both L-xylulose and ascorbic acid 
arise from chemical reduction of glucuronic acid.27 The presence 
and increasing concentrations of both of these acids after con-
trast exposure suggests initial reductive stress followed by an ox-
idative burst, possibly as a result of renal cortical vasospasm re-
sulting in a hypoxia-reoxygenation pattern in the kidney medulla 
induced by contrast exposure in the kidney.28-30 
 Unlike our findings of increasing levels of xylonic acid and thre-
onic acid after contrast exposure, we did identify that concentra-
tions of uracil and glycine changed but not in a uniform direction. 
Attempting to determine a specific metabolic function involving 
uracil is challenging since it is one of the four nucleotides that 
make up RNA and thus its presence is ubiquitous. On the other 
hand, our identification of glycine as a potential marker for CIN is 
consistent with previous animal models.31-33 These animal studies 
showed a protective effect of glycine from both oxidant stress as 
well as cellular hypoxia.31,32 Cellular hypoxia may be a result of 
changes in renal blood flow in response to contrast administration. 
Limitations
This is a pilot trial that was underpowered to detect an associa-
tion of specific metabolites with CIN but rather our focus was to 
identify if metabolomic differences occur in patients with CIN and 
identify metabolites that warrant further investigation. In addi-
tion, due to the small sample size, we were unable to adjust for 
underlying medical illnesses, time since last meal, medications, or 
baseline renal function. Some urine samples were collected out-
side the target range due to inability to void. However these were 
the first urine samples available from the patients. This study did 
not address the clinical relevance of CIN. Specific isomers of me-
tabolites were not defined. 
Summary and clinical implications
CIN is a well described complication of intravenous contrast. Ear-
lier identification of patients at risk may be possible through the 
identification of metabolite patterns that are highly associated 
with the disease, and it may improve the diagnosis. In this study 
we have shown that there are differences in urine metabolites be-
tween  patients who do and do not develop CIN, prior to contrast 
administration and that changes in certain metabolites over time 
are associated with the diagnosis. 
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